This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ACTION - Anticoagulation Treatment Influence on Post-operative Patients

This study has been withdrawn prior to enrollment.
(Study replaced by an observational study)
Information provided by (Responsible Party):
St. Jude Medical Identifier:
First received: September 15, 2005
Last updated: June 4, 2013
Last verified: June 2013
The primary objective of this study is to compare two different regimens of therapy, AVK and ASA (aspirin), in the early postoperative period after aortic valve replacement with SJM Epic™ or SJM Epic™ Supra Porcine Bioprosthetic Heart Valve by establishing the adverse event free survival rate at 3 month post intervention follow-up of the 2 groups(with special focus on thromboembolic events and bleedings).

Condition Intervention Phase
Heart Valve Disease Device: Aortic valve replacement Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial

Resource links provided by NLM:

Further study details as provided by St. Jude Medical:

Enrollment: 0
Study Start Date: September 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient requires, for the first time, isolated aortic valve replacement (pacemaker insertion is allowed)
  2. Patient (or legal guardian) has signed a study specific informed consent form agreeing to the data collection and follow-up requirements.
  3. Patient is of legal age in the host country
  4. The patient is in sinus rhythm before implantation

Exclusion Criteria:

  1. Patient already has a prosthetic valve, other than the valve being replaced at this time.
  2. Patient requires double valve implantation
  3. Patient requires concomitant CABG
  4. Patients requires intra aortic balloon pump at intervention
  5. Patient has a medical condition which contraindicates implantation of the SJM Epic and/or SJM Epic Supra Porcine Bioprosthetic Heart Valve (e.g. patient on dialysis)
  6. Patient requires ASA or AVK therapy, i.e. not suitable for randomization
  7. Patient is pregnant or nursing.
  8. Patient is affected by active endocarditis.
  9. Patient is affected by aortic dissection.
  10. Patient has history of cerebral ischemia
  11. Patient is affected by coagulopathy, history of GI bleeding or increased bleeding risk
  12. Patient is affected by peripheral vascular disease requiring treatment
  13. Patient has previous chronic anticoagulation therapy
  14. Patient is allergic to ASA and/or AVK
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00187304

Sponsors and Collaborators
St. Jude Medical
Principal Investigator: Jean-Phillippe Verhoye, MD CHU Pontchaillou Rennes France
  More Information

Responsible Party: St. Jude Medical Identifier: NCT00187304     History of Changes
Other Study ID Numbers: CS04012TV
Study First Received: September 15, 2005
Last Updated: June 4, 2013

Additional relevant MeSH terms:
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases processed this record on September 21, 2017